AI Verdict
INFU has stronger fundamentals based on our AI analysis.
INO vs INFU Fundamental Comparison
| Metric | INO | INFU |
|---|---|---|
| Revenue | $65,343.0 | $143.4M |
| Net Income | $-84.9M | $6.6M |
| Net Margin | -130,000.0% | 4.6% |
| ROE | -352.5% | 11.6% |
| ROA | -114.3% | 6.6% |
| Current Ratio | 1.40x | 1.80x |
| Debt/Equity | 2.60x | 0.34x |
| EPS | $-1.81 | $0.31 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
INO vs INFU: Frequently Asked Questions
Is INO or INFU a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), INFU has stronger fundamentals. INO is rated STRONG SELL (92% confidence) while INFU is rated BUY (78% confidence). This is not investment advice.
How does INO compare to INFU fundamentally?
INOVIO PHARMACEUTICALS, INC. has ROE of -352.5% vs InfuSystem Holdings, Inc's 11.6%. Net margins are -130,000.0% vs 4.6% respectively.
Which stock pays higher dividends, INO or INFU?
INO has a dividend yield of N/A or no dividend while INFU has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in INO or INFU for long term?
For long-term investing, consider that INO has STRONG SELL rating with 92% confidence, while INFU has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about INO vs INFU?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For INO vs INFU, the AI consensus favors INFU based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.